Alectinib

Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth.

Alectinib have been clinically evaluated for the treatment of patients with ALK-driven tumors.

Potent ALK inhibitor.